WHO advises doctors to not use Remdesivir to treat COVID-19

The WHO advises not to use Gilead Science Inc’s Remdesivir to treat hospitalised COVID-19 patients less than a month after U.S. granted it approval. The medicine has been used in more than 50 countries to reduce recovery time of COVID-19 patients. There is currently no evidence that introduced deaths, instead “it has no meaningful effect”. The limited study was weighted along “Relatively high cost and resource implications” associated with Remdesivir.